Last $4.38 USD
Change Today +0.02 / 0.46%
Volume 670.5K
XOMA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

xoma corp (XOMA) Snapshot

Open
$4.39
Previous Close
$4.36
Day High
$4.41
Day Low
$4.30
52 Week High
03/4/14 - $9.57
52 Week Low
05/8/14 - $3.42
Market Cap
469.0M
Average Volume 10 Days
867.3K
EPS TTM
$-1.04
Shares Outstanding
107.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XOMA CORP (XOMA)

xoma corp (XOMA) Related Bloomberg News

View More Bloomberg News

xoma corp (XOMA) Related Businessweek News

No Related Businessweek News Found

xoma corp (XOMA) Details

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. Its proprietary products comprise gevokizumab, a humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III studies for non-infectious uveitis, Behçet’s uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, cardiovascular disease, Schnitzler syndrome, and other diseases, as well as diseases under the neutrophilic dermatoses designation; and various proof-of-concept studies, including polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. The company’s proprietary products also include XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for the treatment of diabetes patients; XOMA 3AB, a multi-antibody product for the treatment of human botulism poisoning; and XOMA 629, a topical anti-bacterial product for the treatment of human immune system. In addition, it develops ACEON, an angiotensin converting enzyme inhibitor product; FDC1, a perindopril arginine and amlodipine besylate product; and HCD122 and LFA102 programs for the treatment of cancer. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Pfizer Inc.; and Margaux Biologics, Inc. The company was founded in 1981 and is headquartered in Berkeley, California.

180 Employees
Last Reported Date: 08/7/14
Founded in 1981

xoma corp (XOMA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $489.3K
Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: $417.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $347.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $391.4K
Chief Commercial Officer and Vice President
Total Annual Compensation: $380.0K
Compensation as of Fiscal Year 2013.

xoma corp (XOMA) Key Developments

XOMA Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reaffirms Earnings Guidance for the Year 2014

XOMA Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $5,973,000 against $7,151,000 a year ago. Loss from operations was $18,777,000 against $14,079,000 a year ago. Net loss was $11,897,000 or $0.17 per diluted share against $17,248,000 or $0.21 per diluted share a year ago. For the six months, the company reported total revenues of $9,383,000 against $16,605,000 a year ago. Loss from operations was $42,251,000 against $25,402,000 a year ago. Net loss was $16,584,000 or $0.39 per diluted share against $42,135,000 or $0.51 per diluted share a year ago. The Company reconfirmed its anticipated cash used in ongoing operating activities during 2014 will be approximately $55 to $60.0 million. The Company's principal expenditures are towards costs associated with its two gevokizumab Phase 3 clinical programs: the EYEGUARD program and the pyoderma gangrenosum program. The guidance includes expected license and contract-related revenue during the year, which is consistent with its history of entering into such agreements.

XOMA Corporation, Q2 2014 Earnings Call, Aug 07, 2014

XOMA Corporation, Q2 2014 Earnings Call, Aug 07, 2014

XOMA Corporation Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-13-2014 08:35 AM

XOMA Corporation Presents at Wedbush 2014 Life Sciences Management Access Conference, Aug-13-2014 08:35 AM. Venue: Le Parker Meridien, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XOMA:US $4.38 USD +0.02

XOMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €8.50 EUR -0.07
BioInvent International AB kr2.90 SEK +0.01
Dyax Corp $10.21 USD +0.19
Intrexon Corp $20.28 USD +0.16
MorphoSys AG €70.35 EUR +1.09
View Industry Companies
 

Industry Analysis

XOMA

Industry Average

Valuation XOMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XOMA CORP, please visit www.xoma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.